Concenter BioPharma develops drugs for treating and preventing type 2 diabetes.

The company has developed a family of nonsteroidal chemical complexes made from components approved for clinical use.

These new chemical entities constitute a protected platform of drugs with proven efficacy and safety.The members of the platform act as potent anti-inflammatory agents, strong iron-chelating agents, and antibiotic agents.

These modes of action jointly assist in treating the causes and/or symptoms of multiple indications.Concenter BioPharma is a subsidiary of Silkim Pharma.